Men treated for prostate cancer could see the number of radiotherapy treatments they need drastically reduced after a major trial.
The trial, conducted by the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research in London, found fewer treatments of higher doses – stereotactic body radiotherapy (SBRT) – are as effective as a longer series of lower doses delivered over several weeks.
